Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML
27/04/2026 06:02
April 27 (Reuters) - Cantargia AB CANTA.ST: ANNOUNCES EARLY RESULTS FROM PHASE 1B/2A NADUNOLIMAB TRIAL IN MDS AND AML NADUNOLIMAB COMBINATIONS GENERALLY WELL TOLERATED WITH ACCEPTABLE SAFETY PROFILE PHASE 1B DOSE-ESCALATION COMPLETED; STUDY PROGRESSING TO PHASE 2A Source text: ID:nMFNQ2bD4 Further company coverage: CANTA.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML